Minerva Neurosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	32.76	82.4	21.46	41.01	36.19	60.86
Short-Term Investments	45.41	-	-	-	-	-
Cash & Short-Term Investments	78.16	82.4	21.46	41.01	36.19	60.86
Cash Growth	349.48%	283.94%	-47.67%	13.31%	-40.52%	139.05%
Other Current Assets	0.94	0.7	0.81	0.99	3.97	1.35
Total Current Assets	79.11	83.1	22.27	42	40.16	62.2
Net Property, Plant & Equipment	-	-	0.01	0.01	0.02	-
Other Intangible Assets	-	-	-	0.02	0.04	0.05
Goodwill	14.87	14.87	14.87	14.87	14.87	14.87
Other Long-Term Assets	0.05	-	-	-	-	-
Total Assets	94.03	97.97	37.14	56.9	55.09	77.12
Accounts Payable	2.12	0.64	1.61	1.81	0.97	1.85
Accrued Expenses	2.36	1.65	1.23	1.54	0.41	0.97
Total Current Liabilities	4.48	2.29	2.84	3.34	1.38	2.82
Long-Term Debt	60	60	60	82.02	73.73	66.33
Other Long-Term Liabilities	278.6	171.47	-	-	-	-
Total Long-Term Liabilities	338.6	231.47	60	82.02	73.73	66.33
Total Liabilities	343.08	233.76	62.84	85.36	75.11	69.15
Common Stock	0	0	0	0	0	0
Additional Paid-in Capital	560.19	548.05	369.68	368.36	346.79	342.68
Retained Earnings	-814.2	-688.8	-395.38	-396.82	-366.81	-334.7
Total Common Shareholders' Equity	-254.01	-140.75	-25.69	-28.46	-20.02	7.98
Minority Interest	4.96	4.96	-	-	-	-
Shareholders' Equity	-249.05	-135.79	-25.69	-28.46	-20.02	7.98
Total Liabilities & Equity	94.03	97.97	37.14	56.9	55.09	77.12
Total Debt	60	60	60	82.02	73.73	66.33
Net Cash (Debt)	18.16	22.4	-38.54	-41	-37.54	-5.47
Net Cash Growth	-18.91%	-	-	-	-	-
Net Cash Per Share	1.04	2.65	-5.09	-6.30	-6.99	-1.02
Book Value	-254.01	-140.75	-25.69	-28.46	-20.02	7.98
Book Value Per Share	-14.48	-16.63	-3.39	-4.37	-3.73	1.49
Tangible Book Value	-268.88	-155.62	-40.56	-43.34	-34.94	-6.94
Tangible Book Value Per Share	-15.33	-18.39	-5.36	-6.66	-6.51	-1.30

SEC Filings: 10-K · 10-Q